Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Review Article

SGLT-2 Inhibitors and Nephroprotection in Patients with Diabetic and Non-diabetic Chronic Kidney Disease

Author(s): Pantelis Sarafidis*, Eva Pella, Mehmet Kanbay and Aikaterini Papagianni

Volume 30, Issue 18, 2023

Published on: 20 October, 2022

Page: [2039 - 2060] Pages: 22

DOI: 10.2174/0929867329666220825121304

Price: $65

Open Access Journals Promotions 2
Abstract

For several years, blood pressure control and blocking of the renin-angiotensin system (RAS) represented the cornerstones of chronic kidney disease (CKD) treatment. Cardiovascular outcome trials with sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with type 2 diabetes mellitus (DM) suggested that these agents can effectively delay the progression of CKD in these individuals. A major nephroprotective effect of canagliflozin was also shown in a renal outcome trial in patients with proteinuric diabetic CKD. The Study-to- Evaluate-the-Effect- of-Dapagliflozin-on-Renal-Outcomes-and-Cardiovascular- Mortality-in-Patients-With-Chronic-Kidney-Disease (DAPA-CKD) is a recent milestone in the field, as it included patients with both diabetic and non-diabetic proteinuric CKD and showed impressive reduction in the primary renal outcome of CKD progression, as well as the risk of hospitalization for heart failure and all-cause mortality on top of standard- of-care treatment. These benefits were consistent for patients with diabetic and non-diabetic CKD, including patients with ischemic or hypertensive nephropathy and glomerulonephritides (IgA nephropathy, focal segmental glomerulosclerosis and membranous nephropathy). Based on the above, relevant guidelines should accommodate their recommendations to implement treatment with SGLT-2 inhibitors for CKD patients.

Keywords: Diabetic CKD, non-diabetic CKD, glomerulonephritis, SGLT-2 inhibitors, dapagliflozin, canagliflozin.

[1]
Jager, K.J.; Kovesdy, C.; Langham, R.; Rosenberg, M.; Jha, V.; Zoccali, C. A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases. Kidney Int., 2019, 96(5), 1048-1050.
[http://dx.doi.org/10.1016/j.kint.2019.07.012] [PMID: 31582227]
[2]
Bikbov, B.; Purcell, C.A.; Levey, A.S.; Smith, M.; Abdoli, A.; Abebe, M.; Adebayo, O.M.; Afarideh, M.; Agarwal, S.K.; Agudelo, B.M.; Ahmadian, E.; Al-Aly, Z.; Alipour, V.; Almasi-Hashiani, A.; Al-Raddadi, R.M.; Alvis, G.N.; Amini, S.; Andrei, T.; Andrei, C.L.; Andualem, Z.; Anjomshoa, M.; Arabloo, J.; Ashagre, A.F.; Asmelash, D.; Ataro, Z.; Atout, M.M.W.; Ayanore, M.A.; Badawi, A.; Bakhtiari, A.; Ballew, S.H.; Balouchi, A.; Banach, M.; Barquera, S.; Basu, S.; Bayih, M.T.; Bedi, N.; Bello, A.K.; Bensenor, I.M.; Bijani, A.; Boloor, A.; Borzì, A.M.; Cámera, L.A.; Carrero, J.J.; Carvalho, F.; Castro, F.; Catalá-López, F.; Chang, A.R.; Chin, K.L.; Chung, S.C.; Cirillo, M.; Cousin, E.; Dandona, L.; Dandona, R.; Daryani, A.; Das Gupta, R.; Demeke, F.M.; Demoz, G.T.; Desta, D.M.; Do, H.P.; Duncan, B.B.; Eftekhari, A.; Esteghamati, A.; Fatima, S.S.; Fernandes, J.C.; Fernandes, E.; Fischer, F.; Freitas, M.; Gad, M.M.; Gebremeskel, G.G.; Gebresillassie, B.M.; Geta, B.; Ghafourifard, M.; Ghajar, A.; Ghith, N.; Gill, P.S.; Ginawi, I.A.; Gupta, R.; Hafezi, N.N.; Haj, M.A.; Haj, M.A.; Hariyani, N.; Hasan, M.; Hasankhani, M.; Hasanzadeh, A.; Hassen, H.Y.; Hay, S.I.; Heidari, B.; Herteliu, C.; Hoang, C.L.; Hosseini, M.; Hostiuc, M.; Irvani, S.S.N.; Islam, S.M.S.; Jafari Balalami, N.; James, S.L.; Jassal, S.K.; Jha, V.; Jonas, J.B.; Joukar, F.; Jozwiak, J.J.; Kabir, A.; Kahsay, A.; Kasaeian, A.; Kassa, T.D.; Kassaye, H.G.; Khader, Y.S.; Khalilov, R.; Khan, E.A.; Khan, M.S.; Khang, Y.H.; Kisa, A.; Kovesdy, C.P.; Kuate Defo, B.; Kumar, G.A.; Larsson, A.O.; Lim, L.L.; Lopez, A.D.; Lotufo, P.A.; Majeed, A.; Malekzadeh, R.; März, W.; Masaka, A.; Meheretu, H.A.A.; Miazgowski, T.; Mirica, A.; Mirrakhimov, E.M.; Mithra, P.; Moazen, B.; Mohammad, D.K.; Mohammadpourhodki, R.; Mohammed, S.; Mokdad, A.H.; Morales, L.; Moreno Velasquez, I.; Mousavi, S.M.; Mukhopadhyay, S.; Nachega, J.B.; Nadkarni, G.N.; Nansseu, J.R.; Natarajan, G.; Nazari, J.; Neal, B.; Negoi, R.I.; Nguyen, C.T.; Nikbakhsh, R.; Noubiap, J.J.; Nowak, C.; Olagunju, A.T.; Ortiz, A.; Owolabi, M.O.; Palladino, R.; Pathak, M.; Poustchi, H.; Prakash, S.; Prasad, N.; Rafiei, A.; Raju, S.B.; Ramezanzadeh, K.; Rawaf, S.; Rawaf, D.L.; Rawal, L.; Reiner, R.C., Jr; Rezapour, A.; Ribeiro, D.C.; Roever, L.; Rothenbacher, D.; Rwegerera, G.M.; Saadatagah, S.; Safari, S.; Sahle, B.W.; Salem, H.; Sanabria, J.; Santos, I.S.; Sarveazad, A.; Sawhney, M.; Schaeffner, E.; Schmidt, M.I.; Schutte, A.E.; Sepanlou, S.G.; Shaikh, M.A.; Sharafi, Z.; Sharif, M.; Sharifi, A.; Silva, D.A.S.; Singh, J.A.; Singh, N.P.; Sisay, M.M.M.; Soheili, A.; Sutradhar, I.; Teklehaimanot, B.F.; Tesfay, B.; Teshome, G.F.; Thakur, J.S.; Tonelli, M.; Tran, K.B.; Tran, B.X.; Tran Ngoc, C.; Ullah, I.; Valdez, P.R.; Varughese, S.; Vos, T.; Vu, L.G.; Waheed, Y.; Werdecker, A.; Wolde, H.F.; Wondmieneh, A.B.; Wulf Hanson, S.; Yamada, T.; Yeshaw, Y.; Yonemoto, N.; Yusefzadeh, H.; Zaidi, Z.; Zaki, L.; Zaman, S.B.; Zamora, N.; Zarghi, A.; Zewdie, K.A.; Ärnlöv, J.; Coresh, J.; Perico, N.; Remuzzi, G.; Murray, C.J.L.; Vos, T. Global, regional, and national burden of chronic kidney disease, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2020, 395(10225), 709-733.
[http://dx.doi.org/10.1016/S0140-6736(20)30045-3] [PMID: 32061315]
[3]
Go, A.S.; Chertow, G.M.; Fan, D.; McCulloch, C.E.; Hsu, C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med., 2004, 351(13), 1296-1305.
[http://dx.doi.org/10.1056/NEJMoa041031] [PMID: 15385656]
[4]
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl., 2013, 3(1), 1-150.
[5]
Foreman, K.J.; Marquez, N.; Dolgert, A.; Fukutaki, K.; Fullman, N.; McGaughey, M.; Pletcher, M.A.; Smith, A.E.; Tang, K.; Yuan, C.W.; Brown, J.C.; Friedman, J.; He, J.; Heuton, K.R.; Holmberg, M.; Patel, D.J.; Reidy, P.; Carter, A.; Cercy, K.; Chapin, A.; Douwes, S.D.; Frank, T.; Goettsch, F.; Liu, P.Y.; Nandakumar, V.; Reitsma, M.B.; Reuter, V.; Sadat, N.; Sorensen, R.J.D.; Srinivasan, V.; Updike, R.L.; York, H.; Lopez, A.D.; Lozano, R.; Lim, S.S.; Mokdad, A.H.; Vollset, S.E.; Murray, C.J.L. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: Reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet, 2018, 392(10159), 2052-2090.
[http://dx.doi.org/10.1016/S0140-6736(18)31694-5] [PMID: 30340847]
[6]
International Diabetes Federation. IDF Diabetes Atlas, 9th ed. Brussels, Belgium. 2019. Available from: https://diabetesatlas.org/en/resources/ (Accessed on: 2021-10-27).
[7]
Sarwar, N.; Gao, P.; Seshasai, S.R.K.; Gobin, R.; Kaptoge, S.; Di Angelantonio, E.; Ingelsson, E.; Lawlor, D.A.; Selvin, E.; Stampfer, M.; Stehouwer, C.D.A.; Lewington, S.; Pennells, L.; Thompson, A.; Sattar, N.; White, I.R.; Ray, K.K.; Danesh, J. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. Lancet, 2010, 375(9733), 2215-2222.
[http://dx.doi.org/10.1016/S0140-6736(10)60484-9] [PMID: 20609967]
[8]
Afkarian, M.; Sachs, M.C.; Kestenbaum, B.; Hirsch, I.B.; Tuttle, K.R.; Himmelfarb, J.; de Boer, I.H. Kidney disease and increased mortality risk in type 2 diabetes. J. Am. Soc. Nephrol., 2013, 24(2), 302-308.
[http://dx.doi.org/10.1681/ASN.2012070718] [PMID: 23362314]
[9]
US Renal Data System 2019 Annual Data Report: Epidemiology of kidney disease in the United States. Am J Kidney Dis Published Online First, 2019, 31
[http://dx.doi.org/10.1053/j.ajkd.2019.09.002]
[10]
Kramer, A.; Pippias, M.; Noordzij, M.; Stel, V.S.; Andrusev, A.M.; Aparicio-Madre, M.I.; Arribas Monzón, F.E.; Åsberg, A.; Barbullushi, M.; Beltrán, P.; Bonthuis, M.; Caskey, F.J.; Castro de la Nuez, P.; Cernevskis, H.; De Meester, J.; Finne, P.; Golan, E.; Heaf, J.G.; Hemmelder, M.H.; Ioannou, K.; Kantaria, N.; Komissarov, K.; Korejwo, G.; Kramar, R.; Lassalle, M.; Lopot, F.; Macário, F.; Mackinnon, B.; Pálsson, R.; Pechter, Ü.; Piñera, V.C.; Santiuste de Pablos, C.; Segarra, M.A.; Seyahi, N.; Slon Roblero, M.F.; Stojceva, T.O.; Vazelov, E.; Winzeler, R.; Ziginskiene, E.; Massy, Z.; Jager, K.J. The European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) registry annual report 2016: A summary. Clin. Kidney J., 2019, 12(5), 702-720.
[http://dx.doi.org/10.1093/ckj/sfz011] [PMID: 31583095]
[11]
Ruiz, H.G.; Sarafidis, P.; Fernández, M.S.; Waeber, B.; Ruilope, L.M. Global cardiovascular protection in chronic kidney disease. Nat. Rev. Cardiol., 2016, 13(10), 603-608.
[http://dx.doi.org/10.1038/nrcardio.2016.48] [PMID: 27053454]
[12]
Sarafidis, P.A.; Ruilope, L.M. Aggressive blood pressure reduction and renin–angiotensin system blockade in chronic kidney disease: Time for re-evaluation? Kidney Int., 2014, 85(3), 536-546.
[http://dx.doi.org/10.1038/ki.2013.355] [PMID: 24048382]
[13]
Kidney Disease: Improving Global Outcomes (KDIGO) Blood pressure work group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl., 2012, 2, 337-414.
[14]
Cheung, A.K.; Chang, T.I.; Cushman, W.C.; Furth, S.L.; Hou, F.F.; Ix, J.H.; Knoll, G.A.; Muntner, P.; Pecoits, F.R.; Sarnak, M.J.; Tobe, S.W.; Tomson, C.R.V.; Mann, J.F.E. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int., 2021, 99(3), S1-S87.
[http://dx.doi.org/10.1016/j.kint.2020.11.003] [PMID: 33637192]
[15]
Sarafidis, P.; Ferro, C.J.; Morales, E.; Ortiz, A.; Malyszko, J.; Hojs, R.; Khazim, K.; Ekart, R.; Valdivielso, J.; Fouque, D.; London, G.M.; Massy, Z.; Ruggenenti, P.; Porrini, E.; Wiecek, A.; Zoccali, C.; Mallamaci, F.; Hornum, M. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrol. Dial. Transplant., 2019, 34(2), 208-230.
[http://dx.doi.org/10.1093/ndt/gfy407] [PMID: 30753708]
[16]
Sarafidis, P.; Ortiz, A.; Ferro, C.J.; Halimi, J.M.; Kreutz, R.; Mallamaci, F.; Mancia, G.; Wanner, C. Sodium--glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: A new era has already begun. J. Hypertens., 2021, 39(6), 1090-1097.
[http://dx.doi.org/10.1097/HJH.0000000000002776] [PMID: 33443971]
[17]
Sarafidis, P.A.; Li, S.; Chen, S.C.; Collins, A.J.; Brown, W.W.; Klag, M.J.; Bakris, G.L. Hypertension awareness, treatment, and control in chronic kidney disease. Am. J. Med., 2008, 121(4), 332-340.
[http://dx.doi.org/10.1016/j.amjmed.2007.11.025] [PMID: 18374693]
[18]
Williams, B.; Mancia, G.; Spiering, W.; Agabiti Rosei, E.; Azizi, M.; Burnier, M.; Clement, D.L.; Coca, A.; de Simone, G.; Dominiczak, A.; Kahan, T.; Mahfoud, F.; Redon, J.; Ruilope, L.; Zanchetti, A.; Kerins, M.; Kjeldsen, S.E.; Kreutz, R.; Laurent, S.; Lip, G.Y.H.; McManus, R.; Narkiewicz, K.; Ruschitzka, F.; Schmieder, R.E.; Shlyakhto, E.; Tsioufis, C.; Aboyans, V.; Desormais, I. 2018 ESC/ESH Guidelines for the management of arterial hypertension. J. Hypertens., 2018, 36(10), 1953-2041.
[http://dx.doi.org/10.1097/HJH.0000000000001940] [PMID: 30234752]
[19]
Sarafidis, P.A.; Stafylas, P.C.; Kanaki, A.I.; Lasaridis, A.N. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: An updated meta-analysis. Am. J. Hypertens., 2008, 21(8), 922-929.
[http://dx.doi.org/10.1038/ajh.2008.206] [PMID: 18535536]
[20]
Sarafidis, P.; Loutradis, C.; Ortiz, A.; Ruilope, L.M. Blood pressure targets in patients with chronic kidney disease: MDRD and AASK now confirming SPRINT. Clin. Kidney J., 2020, 13(3), sfaa015.
[http://dx.doi.org/10.1093/ckj/sfaa015] [PMID: 32699614]
[21]
Klahr, S.; Levey, A.S.; Beck, G.J.; Caggiula, A.W.; Hunsicker, L.; Kusek, J.W.; Striker, G. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N. Engl. J. Med., 1994, 330(13), 877-884.
[http://dx.doi.org/10.1056/NEJM199403313301301] [PMID: 8114857]
[22]
Agodoa, L.Y.; Appel, L.; Bakris, G.L.; Beck, G.; Bourgoignie, J.; Briggs, J.P.; Charleston, J.; Cheek, D.; Cleveland, W.; Douglas, J.G.; Douglas, M.; Dowie, D.; Faulkner, M.; Gabriel, A.; Gassman, J.; Greene, T.; Hall, Y.; Hebert, L.; Hiremath, L.; Jamerson, K.; Johnson, C.J.; Kopple, J.; Kusek, J.; Lash, J.; Lea, J.; Lewis, J.B.; Lipkowitz, M.; Massry, S.; Middleton, J.; Miller, E.R., III; Norris, K.; O’Connor, D.; Ojo, A.; Phillips, R.A.; Pogue, V.; Rahman, M.; Randall, O.S.; Rostand, S.; Schulman, G.; Smith, W.; Thornley-Brown, D.; Tisher, C.C.; Toto, R.D.; Wright, J.T.J., Jr; Xu, S. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA, 2001, 285(21), 2719-2728.
[http://dx.doi.org/10.1001/jama.285.21.2719] [PMID: 11386927]
[23]
Appel, L.J.; Wright, J.T., Jr; Greene, T.; Agodoa, L.Y.; Astor, B.C.; Bakris, G.L.; Cleveland, W.H.; Charleston, J.; Contreras, G.; Faulkner, M.L.; Gabbai, F.B.; Gassman, J.J.; Hebert, L.A.; Jamerson, K.A.; Kopple, J.D.; Kusek, J.W.; Lash, J.P.; Lea, J.P.; Lewis, J.B.; Lipkowitz, M.S.; Massry, S.G.; Miller, E.R.; Norris, K.; Phillips, R.A.; Pogue, V.A.; Randall, O.S.; Rostand, S.G.; Smogorzewski, M.J.; Toto, R.D.; Wang, X. AASK Collaborative Research Group. Intensive blood-pressure control in hypertensive chronic kidney disease. N. Engl. J. Med., 2010, 363(10), 918-929.
[http://dx.doi.org/10.1056/NEJMoa0910975] [PMID: 20818902]
[24]
Ku, E.; Sarnak, M.J.; Toto, R.; McCulloch, C.E.; Lin, F.; Smogorzewski, M.; Hsu, C. Effect of blood pressure control on long-term risk of end-stage renal disease and death among subgroups of patients with chronic kidney disease. J. Am. Heart Assoc., 2019, 8(16), e012749.
[http://dx.doi.org/10.1161/JAHA.119.012749] [PMID: 31411082]
[25]
Sarafidis, P.A.; Alexandrou, M.E.; Ruilope, L.M. A review of chemical therapies for treating diabetic hypertension. Expert Opin. Pharmacother., 2017, 18(9), 909-923.
[http://dx.doi.org/10.1080/14656566.2017.1328054] [PMID: 28480805]
[26]
Halimi, J.M. The emerging concept of chronic kidney disease without clinical proteinuria in diabetic patients. Diabetes Metab., 2012, 38(4), 291-297.
[http://dx.doi.org/10.1016/j.diabet.2012.04.001] [PMID: 22622176]
[27]
Sarafidis, P.A.; Ruilope, L.M. Cardiorenal disease development under chronic renin–angiotensin–aldosterone system suppression. J. Renin Angiotensin Aldosterone Syst., 2012, 13(1), 217-219.
[http://dx.doi.org/10.1177/1470320312439140] [PMID: 22389391]
[28]
Sarafidis, P.A.; Georgianos, P.I.; Bakris, G.L. Advances in treatment of hyperkalemia in chronic kidney disease. Expert Opin. Pharmacother., 2015, 16(14), 2205-2215.
[http://dx.doi.org/10.1517/14656566.2015.1083977] [PMID: 26330193]
[29]
Sarafidis, P.A.; Blacklock, R.; Wood, E.; Rumjon, A.; Simmonds, S.; Fletcher, R.J.; Ariyanayagam, R.; Al-Yassin, A.; Sharpe, C.; Vinen, K. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clin. J. Am. Soc. Nephrol., 2012, 7(8), 1234-1241.
[http://dx.doi.org/10.2215/CJN.01150112] [PMID: 22595825]
[30]
Sarafidis, P.A.; Stafylas, P.C.; Georgianos, P.I.; Saratzis, A.N.; Lasaridis, A.N. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: A meta-analysis. Am. J. Kidney Dis., 2010, 55(5), 835-847.
[http://dx.doi.org/10.1053/j.ajkd.2009.11.013] [PMID: 20110146]
[31]
Sarafidis, P.A.; Bakris, G.L. Protection of the kidney by thiazolidinediones: An assessment from bench to bedside. Kidney Int., 2006, 70(7), 1223-1233.
[http://dx.doi.org/10.1038/sj.ki.5001620] [PMID: 16883325]
[32]
Stafylas, P.C.; Sarafidis, P.A.; Lasaridis, A.N. Rosiglitazone and cardiovascular risk: Weighing recent evidence. J. Cardiometab. Syndr., 2007, 2(4), 295-296.
[http://dx.doi.org/10.1111/j.1559-4564.2007.07744.x] [PMID: 18059214]
[33]
Stafylas, P.C.; Sarafidis, P.A.; Lasaridis, A.N. The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality. Int. J. Cardiol., 2009, 131(3), 298-304.
[http://dx.doi.org/10.1016/j.ijcard.2008.06.005] [PMID: 18684530]
[34]
Parving, H.H.; Brenner, B.M.; McMurray, J.J.V.; de Zeeuw, D.; Haffner, S.M.; Solomon, S.D.; Chaturvedi, N.; Persson, F.; Desai, A.S.; Nicolaides, M.; Richard, A.; Xiang, Z.; Brunel, P.; Pfeffer, M.A. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N. Engl. J. Med., 2012, 367(23), 2204-2213.
[http://dx.doi.org/10.1056/NEJMoa1208799] [PMID: 23121378]
[35]
Fried, L.F.; Emanuele, N.; Zhang, J.H.; Brophy, M.; Conner, T.A.; Duckworth, W.; Leehey, D.J.; McCullough, P.A.; O’Connor, T.; Palevsky, P.M.; Reilly, R.F.; Seliger, S.L.; Warren, S.R.; Watnick, S.; Peduzzi, P.; Guarino, P. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N. Engl. J. Med., 2013, 369(20), 1892-1903.
[http://dx.doi.org/10.1056/NEJMoa1303154] [PMID: 24206457]
[36]
de Zeeuw, D.; Akizawa, T.; Audhya, P.; Bakris, G.L.; Chin, M.; Christ-Schmidt, H.; Goldsberry, A.; Houser, M.; Krauth, M.; Lambers Heerspink, H.J.; McMurray, J.J.; Meyer, C.J.; Parving, H.H.; Remuzzi, G.; Toto, R.D.; Vaziri, N.D.; Wanner, C.; Wittes, J.; Wrolstad, D.; Chertow, G.M. BEACON Trial Investigators. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N. Engl. J. Med., 2013, 369(26), 2492-2503.
[http://dx.doi.org/10.1056/NEJMoa1306033] [PMID: 24206459]
[37]
Mann, J.F.E.; Green, D.; Jamerson, K.; Ruilope, L.M.; Kuranoff, S.J.; Littke, T.; Viberti, G. ASCEND Study Group. Avosentan for overt diabetic nephropathy. J. Am. Soc. Nephrol., 2010, 21(3), 527-535.
[http://dx.doi.org/10.1681/ASN.2009060593] [PMID: 20167702]
[38]
Heerspink, H.J.L.; Parving, H.H.; Andress, D.L.; Bakris, G.; Correa-Rotter, R.; Hou, F.F.; Kitzman, D.W.; Kohan, D.; Makino, H.; McMurray, J.J.V.; Melnick, J.Z.; Miller, M.G.; Pergola, P.E.; Perkovic, V.; Tobe, S.; Yi, T.; Wigderson, M.; de Zeeuw, D.; Elbert, A.; Vallejos, A.; Alvarisqueta, A.; Maffei, L.; Juncos, L.; de Arteaga, J.; Greloni, G.; Farias, E.; Zucchini, A.; Vogel, D.; Cusumano, A.; Santos, J.; Fraenkel, M.; Gallagher, M.; Davis, T.; Acharya, S.; Cooke, D.; Suranyi, M.; Roger, S.; Toussaint, N.; Pollock, C.; Chan, D.; Stranks, S.; MacIsaac, R.; Endre, Z.; Schmidt, A.; Prager, R.; Mayer, G.; Warling, X.; Jadoul, M.; Hougardy, J.; Vercammen, C.; Van Vlem, B.; Gillard, P.; Costa e Forti, A.; Borges, J.L.; Santos Canani, L.; Eliaschewitz, F.; Leite, S.; Fraige, F.F.; Paschoalin, R.; Moura Neto, J.A.; Deboni, L.; de Lourdes Noronha, I.; Cercato, C.; Prompt, C.A.; Zanella, M.; Rassi, N.; D’Avila, D.; Milagres, R.; Felicio, J.; Pecoits, F.R.; Riella, M.C.; Salles, J.; Keitel, E.; Draibe, S.; Amodeo, C.; Youmbissi, J.; Roy, L.; Cournoyer, S.; Jolly, S.; Pichette, V.; Nesrallah, G.; Bajaj, H.S.; Khandwala, H.; Aronson, R.; Goluch, R.; Tam, P.; Rabbat, C.; Tobe, S.; Bailey, G.; Chow, S.; Castillo, A.; Danin Vargas, A.; Gonzalez, F.; Munoz, R.; Gutierrez, V.; Godoy, G.; Zhao, H.; Liu, Z.; Zhao, M.; Guo, X.; Su, B.; Fu, S.; Xu, Y.; Yang, J.; Shi, B.; Xiao, G.; Shi, W.; Hao, C.; Xing, C.; Hou, F.; Luo, Q.; Li, Y.; Ji, L.; Zuo, L.; Wang, S.; Ni, Z.; Ding, G.; Chen, N.; Zhao, J.; Jia, W.; Yu, S.; Weng, J.; Xu, G.; Fu, P.; Sun, S.; Liu, B.; Ding, X.; Rychlik, I.; Oplustilova, A.; Bartaskova, D.; Honova, V.; Chmelickova, H.; Petr, M.; Bucek, P.; Tesar, V.; Zahumensky, E.; Povlsen, J.; Egstrup, K.; Oczachowska, K.A.; Rossing, P.; Lahtela, J.; Strand, J.; Kantola, I.; Petit, C.; Combe, C.; Zaoui, P.; Esnault, V.; Urena Torres, P.; Halimi, J-M.; Dussol, B.; Bieler, T.; Budde, K.; Dellanna, F.; Segiet, T.; Kosch, C.; Schmidt-Guertler, H.; Schenkenberger, I.; Vielhauer, V.; Pistrosch, F.; Alscher, M.; Hasslacher, C.; Hugo, C.; Muehlfeld, A.; Wanner, C.; Passadakis, P.; Apostolou, T.; Tentolouris, N.; Stefanidis, I.; Mavromatidis, K.; Liakopoulos, V.; Goumenos, D.; Siamopoulos, K.; Yeung, V.; Ozaki, R.; Fung, S.; Tan, K.; Tang, S.; Lui, S.L.; Cheung, S.F.; Sreenan, S.; Eustace, J.; O’Shea, D.; Lavin, P.; Stack, A.; Yagil, Y.; Wainstein, J.; Knobler, H.; Cohen, J.; Kenis, I.; Daoud, D.; Bar, D.Y.; Frajewicki, V.; Adawi, F.; Gesualdo, L.; Santoro, D.; Marino, F.; Galfre, A.; Brunati, C.; Ruggenenti, P.; Rombola, G.; Pugliese, G.; Ravera, M.; Malberti, F.; Pontoriero, G.; Rampino, T.; De Cosmo, S.; Esposito, C.; Nappi, F.; Abaterusso, C.; Conte, G.; Panichi, V.; Lauro, D.; Capasso, G.; Russo, D.; Anzai, J.; Naka, M.; Ato, K.; Tsujimoto, T.; Nimura, T.; Nakashima, E.; Takeda, T.; Fujii, S.; Kobayashi, K.; Iwaoka, H.; Nagayama, K.; Harada, H.; Maeda, H.; Kishimoto, R.; Iitsuka, T.; Itabashi, N.; Furuya, R.; Maeda, Y.; Yamada, D.; Sasaki, N.; Sasaki, H.; Ueda, S.; Kashihara, N.; Watanabe, S.; Nakamura, T.; Kanai, H.; Makita, Y.; Ono, K.; Iehara, N.; Goto, D.; Kosuge, K.; Tsuchida, K.; Sato, T.; Sekikawa, T.; Okamoto, H.; Tanaka, T.; Ikeda, N.; Tadika, T.; Mukasa, K.; Osonoi, T.; Hirano, F.; Nishimura, M.; Yambe, Y.; Tanaka, Y.; Ujihara, M.; Sakai, T.; Imura, M.; Umayahara, Y.; Makino, S.; Nakazawa, J.; Yamaguchi, Y.; Kashine, S.; Miyaoka, H.; Suzuki, K.; Inoue, T.; Nagai, S.; Sato, N.; Yamamoto, M.; Taya, N.; Fujita, A.; Matsutani, A.; Shibagaki, Y.; Sato, Y.; Yamauchi, A.; Tsutsui, M.; Ishiko, T.; Kaneko, S.; Azuma, N.; Matsuda, H.; Hashiguchi, Y.; Onishi, Y.; Tokui, M.; Matsuhisa, M.; Kiyosue, A.; Shinoda, J.; Ishikawa, K.; Ahmad, G.; Vijayasingham, S.; Aziz, N.A.; Hussein, Z.; Fung, Y.K.; Hassan, W.H.H.W.; Wong, H.S.; Goh, B.L.; Ali, N.M.; Merican, N.S.Y.A.; Vaithilingam, I.; Nik Ahmad, N.N.F.; Adam, N.; Sukor, N.; Vengadasalam, V.P.P.; Abdul Kadir, K.; Mohamed, M.; Renoirte Lopez, K.; Leguizamo-Dimas, A.; Chew Wong, A.; Chevaile-Ramos, J.; Gonzalez, G.J.; Rico Hernandez, R.; Nino-Cruz, J.; Sauque Reyna, L.; Gonzalez, G.G.; Madero, R.M.; Bochicchio, R.T.; Aldrete, J.; Carranza, M.J.; Vogt, L.; Smak Gregoor, P.; Barendregt, J.N.M.; Luik, P.; Gansevoort, R.; Laverman, G.; Pilmore, H.; Lunt, H.; Baker, J.; Miller, S.; Rabindranath, K.; Zapata, R.L.; Vargas, G.R.; Calderon Ticona, J.; Dextre Espinoza, A.; Burga Nunez, J.; Zea, N.C.A.; Herrada Orue, B.; Medina, S.B.; Delgado, B.C.; Farfan, A.J.; Mazur, S.; Necki, M.; Wruk, M.; Klodawska, K.; Popenda, G.; Skokowska, E.; Arciszewska, M.; Wiecek, A.; Ciechanowski, K.; Nowicki, M.; Birne, R.; Cabrita, A.; Ramos, A.; Antunes Ferreira, M.A.; Matta Fontanet, E.; Alcantara, A.A.; Comulada, R.A.; Galindo Ramos, E.; Cangiano, J.; Quesada, S.L.; Calderon Ortiz, R.; Vazquez, T.J.; Burgos, C.R.; Rosado, C.; Hancu, N.; Pintilei, E.; Mistodie, C.; Bako, G.; Ionutiu, L.; Petrica, L.; Timar, R.; Tuta, L.; Duma, L.; Tutescu, A.; Ivanova, S.; Essaian, A.; Zrazhevskiy, K.; Tomilina, N.; Smolyarchuk, E.; Kuzin, A.; Lantseva, O.; Karpova, I.; Shamkhalova, M.; Liberanskaya, N.; Yavdosyuk, A.; Shvarts, Y.; Bardymova, T.; Blagoveshchenskaya, O.; Solovev, O.; Rechkova, E.; Pikalova, N.; Pavlova, M.; Kolmakova, E.; Sayfutdinov, R.; Villevalde, S.; Koziolova, N.; Martynenko, V.; Marasaev, V.; Maksudova, A.; Sigitova, O.; Mordovin, V.; Klimontov, V.; Samoylova, Y.; Karonova, T.; Yeoh, L.Y.; Teo, B.W.; Foo, M.W.Y.; Liew, A.; Tkac, I.; Oroszova, A.; Fekete, J.; Rosenberger, J.; Obetkova, I.; Fulopova, A.; Kolesarova, E.; Raslova, K.; Smolko, P.; Oksa, A.; Distiller, L.; Trokis, J.; Adams, L.; Makan, H.; Ramlachan, P.; Mitha, E.; Coetzee, K.; Punt, Z.; Bhorat, Q.; Naiker, P.; Ellis, G.; Van Zyl, L.; Lee, K.W.; Kim, M.S.; Yoo, S.J.; Yoon, K.H.; Cho, Y.W.; Park, T.S.; Kim, S.Y.; Choi, M-G.; Oh, T.K.; Lee, K.W.; Shon, H.S.; Suh, S.H.; Kim, B.J.; Doo, M.K.; Yi, J.H.; Lee, S.A.; Cho, H.C.; Kim, S.G.; Cha, D.R.; Seo, J.A.; Choi, K.M.; Woo, J-T.; Ahn, K.J.; Lee, J.H.; Kim, I-J.; Lee, M-K.; Jang, H.C.; Park, K-S.; Kim, B.S.; Mok, J.O.; Shin, M.; Yoon, S.A.; Nam-Goong, I-S.; Chung, C.H.; Yu, T.Y.; Lee, H.W.; Soto Gonzalez, A.; Almirall, J.; Egido, J.; Calero Gonzalez, F.; Fernandez Fresnedo, G.; Valera Cortes, I.; Praga Terente, M.; Garcia Mendez, I.; Navarro Gonzalez, J.; Herrero Calvo, J.; Cigarran Guldris, S.; Prieto Velasco, M.; Minguela Pesquera, J.I.; Galan, A.; Pascual, J.; Marques Vidas, M.; Martins Munoz, J.; Rodriguez-Perez, J.; Castro-Alonso, C.; Bonet Sol, J.; Seron, D.; Fernandez Giraldez, E.; Arrieta Lezama, J.; Montero, N.; Hernandez-Jaras, J.; Santamaria Olmo, R.; Molas Coten, J.R.; Hellberg, O.; Fellstrom, B.; Bock, A.; Pei, D.; Lin, C-L.; Tien, K-J.; Chen, C-C.; Huang, C-N.; Jiang, J-Y.; Wu, D-A.; Chu, C-H.; Tseng, S-T.; Chen, J-F.; Bau, C-T.; Sheu, W.; Wu, M-S.; Sari, R.; Sezer, S.; Yildiz, A.; Satman, I.; Kalender, B.; Mankovskyy, B.; Fushtey, I.; Stanislavchuk, M.; Kolenyk, M.; Dudar, I.; Zolotaikina, V.; Abrahamovych, O.; Kostynenko, T.; Petrosyan, O.; Kuskalo, P.; Galushchak, O.; Legun, O.; Topchii, I.; Martynyuk, L.; Stryzhak, V.; Panina, S.; Tkach, S.; Korpachev, V.; Maxwell, P.; Gnudi, L.; Kon, S.P.; Tindall, H.; Kalra, P.; Mark, P.; Patel, D.; El-Shahawy, M.; Bai, L.; Nica, R.; Lien, Y-H.; Menefee, J.; Busch, R.; Miller, A.; Ahmed, A.; Arif, A.; Lee, J.; Desai, S.; Bansal, S.; Bentsianov, M.; Belledonne, M.; Jere, C.; Gaona, R.; Greenwood, G.; Brusco, O.; Boiskin, M.; Belo, D.; Minasian, R.; Atray, N.; Lawrence, M.; Taliercio, J.; Pergola, P.; Scott, D.; Alvarez, G.; Marder, B.; Powell, T.; Bakdash, W.; Stoica, G.; McFadden, C.; Rendell, M.; Wise, J.; Jones, A.; Jardula, M.; Madu, I-J.; Varghese, F.; Tulloch, B.; Ahmed, Z.; Hames, M.; Nazeer, I.; Shahid, N.; John, R.; Montero, M.; Fitz-Patrick, D.; Phillips, L.; Guasch, A.; Christofides, E.; Gundroo, A.; Amin, M.; Bowman-Stroud, C.; Link, M.; Mulloy, L.; Nammour, M.; Lalwani, T.; Hanson, L.; Whaley-Connell, A.; Herman, L.; Chatha, R.; Osama, S.; Liss, K.; Kayali, Z.; Bhargava, A.; Israel, E.; Peguero-Rivera, A.; Fang, M.; Slover, J.; Barengolts, E.; Flores, J.; Muoneke, R.; Savin, V.; Awua-Larbi, S.; Levine, A.; Newman, G.; Golestaneh, L.; Bohm, G.; Reisin, E.; Cruz, L.; Weiss, R.; Zieve, F.; Horwitz, E.; Chuang, P.; Mersey, J.; Manley, J.; Graf, R.; Bedros, F.; Joshi, S.; Frias, J.; Assefi, A.; O’Shaughnessy, A.; Brantley, R.; Minga, T.; Tietjen, D.; Kantor, S.; Jamal, A.; Guadiz, R.; Hershon, K.; Bressler, P.; Kopyt, N.; Cathcart, H.; Bloom, S.; Reichel, R.; Nakhle, S.; Dulude, E.; Tarkan, J.; Baker, P.; Zeig, S.; Moya Hechevarria, J.; Ropero-Cartier, A.; De la Calle, G.; Doshi, A.; Saba, F.; Sligh, T.; Shaw, S.; Kumar, J.; Szerlip, H.; Bayliss, G.; Perlman, A.; Sakhrani, L.; Gouge, S.; Argoud, G.; Acosta, I.; Elder, J.; Joshi, S.; Sensenbrenner, J.; Vicks, S.; Mangoo-Karim, R.; Galphin, C.; Leon-Forero, C.; Gilbert, J.; Brown, E.; Ijaz, A.; Butt, S.; Markell, M.; Arauz-Pacheco, C.; Sloan, L.; Alvarado, O.; Jabbour, S.; Simon, E.; Rastogi, A.; James, S.; Bakris, G.; Hall, K.; Melish, J.; Dixon, B.; Adolphe, A.; Kovesdy, C.; Beddhu, S.; Solomon, R.; Fernando, R.; Levin, E.; Thakar, C.; Robey, B.; Goldfarb, D.; Fried, L.; Maddukuri, G.; Thomson, S.; Annand, A.; Kronfli, S.; Kalirao, P.; Schmidt, R.; Dahl, N.; Blumenthal, S.; Weinstein, D.; Ostergaard, O.; Weinstein, T.; Ono, Y.; Yalcin, M.; Karim, S. SONAR Committees and Investigators. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): A double blind, randomised, placebo controlled trial. Lancet, 2019, 393(10184), 1937-1947.
[http://dx.doi.org/10.1016/S0140-6736(19)30772-X] [PMID: 30995972]
[39]
A Phase 3, randomized, double blind, placebo controlled study of atrasentan in patients with IgA nephropathy at risk of progressive loss of renal function. NCT04573478, 2021.
[40]
Bakris, G.L.; Agarwal, R.; Anker, S.D.; Pitt, B.; Ruilope, L.M.; Rossing, P.; Kolkhof, P.; Nowack, C.; Schloemer, P.; Joseph, A.; Filippatos, G. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N. Engl. J. Med., 2020, 383(23), 2219-2229.
[http://dx.doi.org/10.1056/NEJMoa2025845] [PMID: 33264825]
[41]
A randomized, double blind, placebo controlled, parallel group, multicenter, event driven phase 3 study to investigate efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care. NCT02545049, 2021.
[42]
Ruilope, L.M.; Agarwal, R.; Anker, S.D.; Bakris, G.L.; Filippatos, G.; Nowack, C.; Kolkhof, P.; Joseph, A.; Mentenich, N.; Pitt, B. Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial. Am. J. Nephrol., 2019, 50(5), 345-356.
[http://dx.doi.org/10.1159/000503712] [PMID: 31665733]
[43]
Pitt, B.; Filippatos, G.; Agarwal, R.; Anker, S.D.; Bakris, G.L.; Rossing, P.; Joseph, A.; Kolkhof, P.; Nowack, C.; Schloemer, P.; Ruilope, L.M. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N. Engl. J. Med., 2021, 385(24), 2252-2263.
[http://dx.doi.org/10.1056/NEJMoa2110956] [PMID: 34449181]
[44]
FDA approves drug to reduce risk of serious kidney and heart complications in adults with chronic kidney disease associated with type 2 diabetes. FDA , 2021. Available from: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-reduce-risk-serious-kidney-and-heart-complications-adults-chronic-kidney-disease#:~:text=FDA%20has%20approved%20Kerendia%20(fine- renone,associated%20with%20type%202%20diabetes.
[45]
Forxiga. European Medicines Agency. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/forxiga (Accessed on: 2021-10-27).
[46]
Dandona, P.; Mathieu, C.; Phillip, M.; Hansen, L.; Tschöpe, D.; Thorén, F.; Xu, J.; Langkilde, A.M.; Proietto, J.; Stranks, S.; Chen, R.; O’Neal, D.; Pape, A.; Forbes, M.; Morbey, C.; Luger, A.; Hanusch, U.; Schnack, C.; Fliesser, G.E.; Hoelzl, B.; Ebenbichler, C.; Prager, R.; Van Gaal, L.; Vercammen, C.; Scheen, A.; Mathieu, C.; Duyck, F.; Nobels, F.; Ruige, J.; Aggarwal, N.; Woo, V.; St-Pierre, B.; Dumas, R.; Hramiak, I.; Elliott, T.; Hansen, T.K.; Henriksen, J.E.; Gram, J.; Lihn, A.; Bruun, J.; Saltevo, J.; Taurio, J.; Strand, J.; Valle, T.; Nieminen, S.; Pietilainen, K.; Guerci, B.; Hadjadj, S.; Cariou, B.; Verges, B.; Borot, S.; Penfornis, A.; Tschöpe, D.; Schaum, T.; Marck, C.; Horacek, T.; Rose, L.; Klausmann, G.; Luedemann, J.; Appelt, S.; Aigner, U.; Goebel, R.; Behnke, T.; Ziegler, A-G.; Peterfai, E.; Kerenyi, Z.; Oroszlan, T.; Kiss, G.G.; Konyves, L.; Piros, G.; Phillip, M.; Mosenzon, O.; Shehadeh, N.; Adawi, F.; Wainstein, J.; Dotta, F.; Piatti, P.; Genovese, S.; Consoli, A.; Di Bartolo, P.; Mannucci, E.; Giordano, C.; Lapolla, A.; Aguilar, C.; Bazzoni Ruiz, A.E.; Mondragon Ramirez, G.; Orozco, E.P.; Stobschinski de Alba, C.A.; Medina Pech, C.E.; Garza Ruiz, J.; Sauque Reyna, L.; Llamas Esperon, G.; Nevarez Ruiz, L.A.; Velazquez, M.V.; Flores Lozano, F.; Gonzalez Gonzalez, J.G.; Garcia-Hernandez, P.A.; Araujo Silva, R.; Villeda-Espinosa, E.; Mistodie, C.; Popescu, D.; Constantin, C.; Nicolau, A.; Popa, B.; Timar, R.; Serafinceanu, C.; Pintilei, E.; Soto, A.; Gimenez, M.; Merino, J.; Morales, C.; Mezquita, P.; Jendle, J.; Tengmark, B-O.; Eriksson, J.; Londahl, M.; Eliasson, B.; Gunstone, A.; Heller, S.R.; Darzy, K.; Mansell, P.; Davies, M.; Reed, R.; Browne, D.; Courtney, H.; Turner, W.; Blagden, M.; McCrimmon, R.; Dandona, P.; Bergenstal, R.; Lane, W.; Lucas, K.; White, A.; Bao, S.; White, J.; Jantzi, C.; Rasouli, N.; Ervin, W.; Lewy, A.L.; Handelsman, Y.; Miranda, P.B.; Cleland, A.; Fink, R.; Rodbard, H.; Nakhle, S.; Greenberg, C.; Schorr, A.; Bays, H.; Simmons, D.; Klein, E.; Kane, L.; Fishman, N.; Ipp, E.; Garg, S.; Bhargava, A.; Singh, M.Z.; Rosenstock, J.; Thrasher, J.; Warren, M.; Young, L.; Aroda, V.; Pettus, J.; Liljenquist, D.; Busch, R.; Wise, J.; Kayne, D.; Biggs, W. DEPICT-1 Investigators. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: The DEPICT-1 52-week study. Diabetes Care, 2018, 41(12), 2552-2559.
[http://dx.doi.org/10.2337/dc18-1087] [PMID: 30352894]
[47]
Loutradis, C.; Papadopoulou, E.; Angeloudi, E.; Karagiannis, A.; Sarafidis, P. The beneficial actions of SGLT-2 inhibitors beyond management of hyperglycemia. Curr. Med. Chem., 2019.
[http://dx.doi.org/10.2174/0929867326666191029111713] [PMID: 31663470]
[48]
Piperidou, A.; Loutradis, C.; Sarafidis, P. SGLT-2 inhibitors and nephroprotection: Current evidence and future perspectives. J. Hum. Hypertens., 2020.
[http://dx.doi.org/10.1038/s41371-020-00393-4] [PMID: 32778748]
[49]
Imprialos, K.P.; Sarafidis, P.A.; Karagiannis, A.I. Sodium–glucose cotransporter-2 inhibitors and blood pressure decrease. J. Hypertens., 2015, 33(11), 2185-2197.
[http://dx.doi.org/10.1097/HJH.0000000000000719] [PMID: 26372321]
[50]
Mancia, G.; Cannon, C.P.; Tikkanen, I.; Zeller, C.; Ley, L.; Woerle, H.J.; Broedl, U.C.; Johansen, O.E. Impact of empagliflozin on blood pressure in patients with type 2 diabetes mellitus and hypertension by background antihypertensive medication. Hypertension, 2016, 68(6), 1355-1364.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.116.07703] [PMID: 27977392]
[51]
Papadopoulou, E.; Loutradis, C.; Tzatzagou, G.; Kotsa, K.; Zografou, I.; Minopoulou, I.; Theodorakopoulou, M.P.; Tsapas, A.; Karagiannis, A.; Sarafidis, P. Dapagliflozin decreases ambulatory central blood pressure and pulse wave velocity in patients with type 2 diabetes: A randomized, double blind, placebo controlled clinical trial. J. Hypertens., 2021, 39(4), 749-758.
[http://dx.doi.org/10.1097/HJH.0000000000002690] [PMID: 33186325]
[52]
Cherney, D.Z.I.; Cooper, M.E.; Tikkanen, I.; Pfarr, E.; Johansen, O.E.; Woerle, H.J.; Broedl, U.C.; Lund, S.S. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. Kidney Int., 2018, 93(1), 231-244.
[http://dx.doi.org/10.1016/j.kint.2017.06.017] [PMID: 28860019]
[53]
Jordan, J.; Tank, J.; Heusser, K.; Heise, T.; Wanner, C.; Heer, M.; Macha, S.; Mattheus, M.; Lund, S.S.; Woerle, H.J.; Broedl, U.C. The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus. J. Am. Soc. Hypertens., 2017, 11(9), 604-612.
[http://dx.doi.org/10.1016/j.jash.2017.07.005] [PMID: 28757109]
[54]
Chilton, R.; Tikkanen, I.; Cannon, C.P.; Crowe, S.; Woerle, H.J.; Broedl, U.C.; Johansen, O.E. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes. Metab., 2015, 17(12), 1180-1193.
[http://dx.doi.org/10.1111/dom.12572] [PMID: 26343814]
[55]
Piperidou, A.; Sarafidis, P.; Boutou, A.; Thomopoulos, C.; Loutradis, C.; Alexandrou, M.E.; Tsapas, A.; Karagiannis, A. The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus. J. Hypertens., 2019, 37(7), 1334-1343.
[http://dx.doi.org/10.1097/HJH.0000000000002050] [PMID: 31145707]
[56]
Zinman, B.; Wanner, C.; Lachin, J.M.; Fitchett, D.; Bluhmki, E.; Hantel, S.; Mattheus, M.; Devins, T.; Johansen, O.E.; Woerle, H.J.; Broedl, U.C.; Inzucchi, S.E. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med., 2015, 373(22), 2117-2128.
[http://dx.doi.org/10.1056/NEJMoa1504720] [PMID: 26378978]
[57]
Wanner, C.; Inzucchi, S.E.; Lachin, J.M.; Fitchett, D.; von Eynatten, M.; Mattheus, M.; Johansen, O.E.; Woerle, H.J.; Broedl, U.C.; Zinman, B. EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med., 2016, 375(4), 323-334.
[http://dx.doi.org/10.1056/NEJMoa1515920] [PMID: 27299675]
[58]
Perkovic, V.; de Zeeuw, D.; Mahaffey, K.W.; Fulcher, G.; Erondu, N.; Shaw, W.; Barrett, T.D.; Weidner-Wells, M.; Deng, H.; Matthews, D.R.; Neal, B. Canagliflozin and renal outcomes in type 2 diabetes: Results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol., 2018, 6(9), 691-704.
[http://dx.doi.org/10.1016/S2213-8587(18)30141-4] [PMID: 29937267]
[59]
Neal, B.; Perkovic, V.; de Zeeuw, D.; Mahaffey, K.W.; Fulcher, G.; Stein, P.; Desai, M.; Shaw, W.; Jiang, J.; Vercruysse, F.; Meininger, G.; Matthews, D. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial. Am. Heart J., 2013, 166(2), 217-223.e11.
[http://dx.doi.org/10.1016/j.ahj.2013.05.007] [PMID: 23895803]
[60]
Neal, B.; Perkovic, V.; Matthews, D.R.; Mahaffey, K.W.; Fulcher, G.; Meininger, G.; Erondu, N.; Desai, M.; Shaw, W.; Vercruysse, F.; Yee, J.; Deng, H.; de Zeeuw, D. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial. Diabetes Obes. Metab., 2017, 19(3), 387-393.
[http://dx.doi.org/10.1111/dom.12829] [PMID: 28120497]
[61]
Neuen, B.L.; Ohkuma, T.; Neal, B.; Matthews, D.R.; de Zeeuw, D.; Mahaffey, K.W.; Fulcher, G.; Desai, M.; Li, Q.; Deng, H.; Rosenthal, N.; Jardine, M.J.; Bakris, G.; Perkovic, V. Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function. Circulation, 2018, 138(15), 1537-1550.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.035901] [PMID: 29941478]
[62]
Perkovic, V.; Jardine, M.J.; Neal, B.; Bompoint, S.; Heerspink, H.J.L.; Charytan, D.M.; Edwards, R.; Agarwal, R.; Bakris, G.; Bull, S.; Cannon, C.P.; Capuano, G.; Chu, P.L.; de Zeeuw, D.; Greene, T.; Levin, A.; Pollock, C.; Wheeler, D.C.; Yavin, Y.; Zhang, H.; Zinman, B.; Meininger, G.; Brenner, B.M.; Mahaffey, K.W. CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med., 2019, 380(24), 2295-2306.
[http://dx.doi.org/10.1056/NEJMoa1811744] [PMID: 30990260]
[63]
Dapagliflozin effect on cardiovascular events a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the effect of dapagliflozin 10 mg once daily on the incidence of cardiovascular death, myocardial infarction or ischemic stroke in patients with type 2 diabetes. Patent NCT01730534, 2019.
[64]
Wiviott, S.D.; Raz, I.; Bonaca, M.P.; Mosenzon, O.; Kato, E.T.; Cahn, A.; Silverman, M.G.; Zelniker, T.A.; Kuder, J.F.; Murphy, S.A.; Bhatt, D.L.; Leiter, L.A.; McGuire, D.K.; Wilding, J.P.H.; Ruff, C.T.; Gause-Nilsson, I.A.M.; Fredriksson, M.; Johansson, P.A.; Langkilde, A.M.; Sabatine, M.S. DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med., 2019, 380(4), 347-357.
[http://dx.doi.org/10.1056/NEJMoa1812389] [PMID: 30415602]
[65]
Davies, M.J.; D’Alessio, D.A.; Fradkin, J.; Kernan, W.N.; Mathieu, C.; Mingrone, G.; Rossing, P.; Tsapas, A.; Wexler, D.J.; Buse, J.B. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2018, 41(12), 2669-2701.
[http://dx.doi.org/10.2337/dci18-0033] [PMID: 30291106]
[66]
A study to evaluate the effect of dapagliflozin on renal outcomes and cardiovascular mortality in patients with chronic kidney disease. NCT03036150, 2021.
[67]
Heerspink, H.J.L.; Stefánsson, B.V.; Correa, R.R.; Chertow, G.M.; Greene, T.; Hou, F.F.; Mann, J.F.E.; McMurray, J.J.V.; Lindberg, M.; Rossing, P.; Sjöström, C.D.; Toto, R.D.; Langkilde, A.M.; Wheeler, D.C. DAPA-CKD trial committees and investigators. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med., 2020, 383(15), 1436-1446.
[http://dx.doi.org/10.1056/NEJMoa2024816] [PMID: 32970396]
[68]
Wheeler, D.C.; Stefansson, B.V.; Batiushin, M.; Bilchenko, O.; Cherney, D.Z.I.; Chertow, G.M.; Douthat, W.; Dwyer, J.P.; Escudero, E.; Pecoits, F.R.; Furuland, H.; Górriz, J.L.; Greene, T.; Haller, H.; Hou, F.F.; Kang, S.W.; Isidto, R.; Khullar, D.; Mark, P.B.; McMurray, J.J.V.; Kashihara, N.; Nowicki, M.; Persson, F.; Correa-Rotter, R.; Rossing, P.; Toto, R.D.; Umanath, K.; Van Bui, P.; Wittmann, I.; Lindberg, M.; Sjöström, C.D.; Langkilde, A.M.; Heerspink, H.J.L. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: Baseline characteristics. Nephrol. Dial. Transplant., 2020, 35(10), 1700-1711.
[http://dx.doi.org/10.1093/ndt/gfaa234] [PMID: 32862232]
[69]
Heerspink, H.J.L.; Jongs, N.; Chertow, G.M.; Langkilde, A.M.; McMurray, J.J.V.; Correa-Rotter, R.; Rossing, P.; Sjöström, C.D.; Stefansson, B.V.; Toto, R.D.; Wheeler, D.C.; Greene, T. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: A prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol., 2021, 9(11), 743-754.
[http://dx.doi.org/10.1016/S2213-8587(21)00242-4] [PMID: 34619108]
[70]
Jongs, N.; Greene, T.; Chertow, G.M.; McMurray, J.J.V.; Langkilde, A.M.; Correa-Rotter, R.; Rossing, P.; Sjöström, C.D.; Stefansson, B.V.; Toto, R.D.; Wheeler, D.C.; Heerspink, H.J.L. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: A prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol., 2021, 9(11), 755-766.
[http://dx.doi.org/10.1016/S2213-8587(21)00243-6] [PMID: 34619106]
[71]
McMurray, J.J.V.; Wheeler, D.C.; Stefánsson, B.V.; Jongs, N.; Postmus, D.; Correa, R.R.; Chertow, G.M.; Greene, T.; Held, C.; Hou, F.F.; Mann, J.F.E.; Rossing, P.; Sjöström, C.D.; Toto, R.D.; Langkilde, A.M.; Heerspink, H.J.L. Effect of dapagliflozin on clinical outcomes in patients with chronic kidney disease, with and without cardiovascular disease. Circulation, 2021, 143(5), 438-448.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.120.051675] [PMID: 33186054]
[72]
McMurray, J.J.V.; Wheeler, D.C.; Stefánsson, B.V.; Jongs, N.; Postmus, D.; Correa-Rotter, R.; Chertow, G.M.; Hou, F.F.; Rossing, P.; Sjöström, C.D.; Solomon, S.D.; Toto, R.D.; Langkilde, A.M.; Heerspink, H.J.L. Effects of dapagliflozin in patients with kidney disease, with and without heart failure. JACC Heart Fail., 2021, 9(11), 807-820.
[http://dx.doi.org/10.1016/j.jchf.2021.06.017] [PMID: 34446370]
[73]
Heerspink, H.J.L.; Sjöström, C.D.; Jongs, N.; Chertow, G.M.; Kosiborod, M.; Hou, F.F.; McMurray, J.J.V.; Rossing, P.; Correa-Rotter, R.; Kurlyandskaya, R.; Stefansson, B.V.; Toto, R.D.; Langkilde, A.M.; Wheeler, D.C.; Heerspink, H.J.L.; Wheeler, D.C.; Chertow, G.; Correa-Rotter, R.; Greene, T.; Fan Hou, F.; McMurray, J.; Rossing, P.; Toto, R.; Stefansson, B.; Maria Langkilde, A.; Maffei, L.E.; Raffaele, P.; Solis, S.E.; Arias, C.A.; Aizenberg, D.; Luquez, C.; Zaidman, C.; Cluigt, N.; Mayer, M.; Alvarisqueta, A.; Wassermann, A.; Maldonado, R.; Bittar, J.; Maurich, M.; Gaite, L.E.; Garcia, N.; Sivak, L.; Ramallo, P.O.; Santos, J.C.; Garcia Duran, R.; Oddino, J.A.; Maranon, A.; Maia, L.N.; D Avila, D.; Barros, E.J.G.; Vidotti, M.H.; Panarotto, D.; Noronha, I.D.L.; Turatti, L A A.; Deboni, L.; Canziani, M.E.; Riella, M.C.; Bacci, M.R.; Paschoalin, R.P.; Franco, R.J.; Goldani, J.C.; St-Amour, E.; Steele, A.W.; Goldenberg, R.; Pandeya, S.; Bajaj, H.; Cherney, D.; Kaiser, S.M.; Conway, J.R.; Chow, S.S.; Bailey, G.; Lafrance, J.; Winterstein, J.; Cournoyer, S.; Gaudet, D.; Madore, F.; Houlden, R.L.; Dowell, A.; Langlois, M.; Muirhead, N.; Khandwala, H.; Levin, A.; Hou, F.; Xue, Y.; Zuo, L.; Hao, C.; Ni, Z.; Xing, C.; Chen, N.; Dong, Y.; Zhou, R.; Xiao, X.; Zou, Y.; Wang, C.; Liu, B.; Chen, Q.; Lin, M.; Luo, Q.; Zhang, D.; Wang, J.; Chen, M.; Wang, X.; Zhong, A.; Dong, J.; Zhu, C.; Yan, T.; Luo, P.; Ren, Y.; Pai, P.; Li, D.; Zhang, R.; Zhang, J.; Xu, M.; Zhuang, Y.; Kong, Y.; Yao, X.; Peng, X.; Persson, F.I.; Hansen, T.K.; Borg, R.; Pedersen Bjergaard, U.; Hansen, D.; Hornum, M.; Haller, H.; Klausmann, G.; Tschope, D.; Kruger, T.; Gross, P.; Hugo, C.; Obermuller, N.; Rose, L.; Mertens, P.; Zeller-Stefan, H.; Fritsche, A.; Renders, L.; Muller, J.; Budde, K.; Schroppel, B.; Wittmann, I.; Voros, P.; Dudas, M.; Tabak, G.A.; Kirschner, R.; Letoha, A.; Balku, I.; Hermanyi, Z.; Zakar, G.; Mezei, I.; Nagy, G.G.; Lippai, J.; Nemeth, A.; Khullar, D.; Gowdaiah, P.K.; Fernando Mervin, E.; Rao, V.A.; Dewan, D.; Maddi, V.S.K.; Vyawahare, M.S.; Pulichikkat, R.K.; Sonkar, S.K.; Gupta, V.K.; Agarwal, S.; Asirvatham, A.J.; Ignatius, A.; Chaubey, S.; Melemadathil, S.; Alva, H.; Kadam, Y.; Shimizu, H.; Sueyoshi, A.; Takeoka, H.; Abe, Y.; Imai, T.; Onishi, Y.; Fujita, Y.; Tokita, Y.; Makita, Y.; Idogaki, A.; Koyama, R.; Kikuchi, H.; Kashihara, N.; Hayashi, T.; Ando, Y.; Tanaka, T.; Shimizu, M.; Hidaka, S.; Gohda, T.; Tamura, K.; Abe, M.; Kamijo, Y.; Imasawa, T.; Takahashi, Y.; Nakayama, M.; Tomita, M.; Hirano, F.; Nakayama, M.; Fukushima, Y.; Kiyosue, A.; Kurioka, S.; Imai, E.; Kitagawa, K.; Waki, M.; Wada, J.; Uehara, K.; Iwatani, H.; Ota, K.; Shibazaki, S.; Tamura, K.; Katayama, K.; Narita, I.; Iinuma, M.; Matsueda, S.; Sasaki, S.; Yokochi, A.; Tsukamoto, T.; Yoshimura, T.; Kang, S.; Lee, S.; Lim, C.S.; Chin, H.; Joo, K.W.; Han, S.Y.; Chang, T.I.; Park, S.; Park, H.; Park, C.W.; Han, B.G.; Cha, D.R.; Yoon, S.A.; Kim, W.; Kim, S.W.; Ryu, D.; Correa, R.R.; Irizar Santana, S.S.; Hernandez, L.G.; Valdez, O.R.; Secchi, N.C.; Gonzalez, G.G.; Lazcano, J.R.; Bochicchio, R.T.; Bayram, E.A.; Ramos, D.R.; Melo, M.G.S.; Gonzalez, J.G.; Sanchez, J.H.; Madero, R.M.; Garcia, C.A.; Manrique, H.A.; Farfan, J.C.; Vargas, R.; Valdivia, A.; Dextre, A.; Escudero, E.; Calderon Ticona, J.R.; Gonzales, L.; Villena, J.; Leon, L.; Molina, G.; Saavedra, A.; Garrido, E.; Arbanil, H.; Vargas, M.S.; Rodriguez, J.; Isidto, R.; Villaflor, A.J.; Gumba, M.A.; Tirador, L.; Comia, R.S.; Sy, R.A.; Guanzon, M.L.V.V.; Aquitania, G.; De Asis, N.C.; Silva, A.A.; Lim, M.E.; Danguilan, R.A.; Nowicki, M.; Rudzki, H.; Landa, K.; Kucharczyk, B.I.; Gogola, M.B.; Golski, M.; Olech, C.A.; Stompor, T.; Szczepanik, T.; Miklaszewicz, B.; Sciborski, R.; Kuzniewski, M.; Ciechanowski, K.; Wronska, D.; Klatko, W.; Mazur, S.; Popenda, G.; Myslicki, M.; Bolieva, L.Z.; Berns, S.; Galyavich, A.; Abissova, T.; Karpova, I.; Platonov, D.; Koziolova, N.; Kvitkova, L.; Nilk, R.; Medina, T.; Rebrov, A.; Rossovskaya, M.; Sinitsina, I.; Vishneva, E.; Zagidullin, N.; Novikova, T.; Krasnopeeva, N.; Magnitskaya, O.; Antropenko, N.; Batiushin, M.; Escudero Quesada, V.; Barrios Barrea, C.; Espinel Garauz, E.; Cruzado Garrit, J.M.; Morales Portillo, C.; Gorriz Teruel, J.L.; Cigarran Guldris, S.; Praga Terente, M.; Robles Perez-Monteoliva, N.R.; Infanta Cristina, H.; Tinahones Madueno, F.J.; Soto Gonzalez, A.; Diaz Rodriguez, C.; Furuland, H.; Saeed, A.; Dreja, K.; Spaak, J.; Bruchfeld, A.; Kolesnyk, M.; Levchenko, O.; Pyvovarova, N.; Stus, V.; Doretskyy, V.; Korobova, N.; Horoshko, O.; Katerenchuk, I.; Mostovoy, Y.M.; Orynchak, M.; Legun, O.; Dudar, I.; Bilchenko, O.; Andreychyn, S.; Levchenko, A.; Zub, L.; Tereshchenko, N.; Topchii, I.; Ostapenko, T.; Bezuglova, S.; Kopytsya, M.; Turenko, O.; Mark, P.; Barratt, J.; Bhandari, S.; Fraser, D.; Kalra, P.; Kon, S.P.; Mccafferty, K.; Mikhail, A.; Kon, S.P.; Alvarado, O.P.; Anderson, R.; Andrawis, N.S.; Arif, A.; Benjamin, S.A.; Bueso, G.; Busch, R.S.; Carr, K.W.; Carr, K.W.; Crawford, P.; Daboul, N.; De La Calle, G.M.; Delgado, B.; Earl, J.; El-Shahawy, M.A.; Graf, R.J.; Greenwood, G.; Guevara, A.; Wendland, E.M.; Mayfield, R.K.; Montero, M.; Morin, D.J.; Narayan, P.; Numrungroad, V.; Reddy, A.C.; Reddy, R.; Samson, M.B.; Trejo, R.; Butcher, M.B.; Wise, J.K.; Zemel, L.R.; Raikhel, M.; Weinstein, D.; Hernandez, P.; Wynne, A.; Khan, B.V.; Sterba, G.A.; Jamal, A.; Ross, D.; Rovner, S.F.; Tan, A.; Ovalle, F.; Patel, R.J.; Talano, J.; Patel, D.R.; Burgner, A.; Aslam, N.; Elliott, M.; Goral, S.; Jovanovich, A.; Umanath, K.; Waguespack, D.; Weiner, D.; Yu, M.; Schneider, L.; Le, T.; D, T.; Nguyen, N.; Nguyen, H.; Nguyen, D.; Nguyen, V.; Do, T.; Chu, P.; Ta, D.; Tran, N.; Nguyen, D.; Pfeffer, M.A.; Pocock, S.; Swedberg, K.; Rouleau, J.L.; Chaturvedi, N.; Ivanovich, P.; Levey, A.S.; Held, C.; Christersson, C.; Mann, J.; Varenhorst, C. Effects of dapagliflozin on mortality in patients with chronic kidney disease: A pre-specified analysis from the DAPA-CKD randomized controlled trial. Eur. Heart J., 2021, 42(13), 1216-1227.
[http://dx.doi.org/10.1093/eurheartj/ehab094] [PMID: 33792669]
[74]
Sarafidis, P.; Papadopoulos, C.E.; Kamperidis, V.; Giannakoulas, G.; Doumas, M. Cardiovascular protection with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in chronic kidney disease. Hypertension, 2021, 77(5), 1442-1455.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.121.17005] [PMID: 33775130]
[75]
Wheeler, D.C.; Stefánsson, B.V.; Jongs, N.; Chertow, G.M.; Greene, T.; Hou, F.F.; McMurray, J.J.V.; Correa, R.R.; Rossing, P.; Toto, R.D.; Sjöström, C.D.; Langkilde, A.M.; Heerspink, H.J.L. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: A prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol., 2021, 9(1), 22-31.
[http://dx.doi.org/10.1016/S2213-8587(20)30369-7] [PMID: 33338413]
[76]
Wheeler, D.C.; Toto, R.D.; Stefánsson, B.V.; Jongs, N.; Chertow, G.M.; Greene, T.; Hou, F.F.; McMurray, J.J.V.; Pecoits, F.R.; Correa, R.R.; Rossing, P.; Sjöström, C.D.; Umanath, K.; Langkilde, A.M.; Heerspink, H.J.L. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int., 2021, 100(1), 215-224.
[http://dx.doi.org/10.1016/j.kint.2021.03.033] [PMID: 33878338]
[77]
Barratt, J.; Floege, J. SGLT-2 inhibition in IgA nephropathy: The new standard of care? Kidney Int., 2021, 100(1), 24-26.
[http://dx.doi.org/10.1016/j.kint.2021.04.002] [PMID: 33878337]
[78]
Anders, H.J.; Peired, A.J.; Romagnani, P. SGLT2 inhibition requires reconsideration of fundamental paradigms in chronic kidney disease, ‘diabetic nephropathy’, IgA nephropathy and podocytopathies with FSGS lesions. Nephrol. Dial. Transplant., 2020, gfaa329.
[http://dx.doi.org/10.1093/ndt/gfaa329] [PMID: 33313878]
[79]
Chertow, G.M.; Vart, P.; Jongs, N.; Toto, R.D.; Gorriz, J.L.; Hou, F.F.; McMurray, J.J.V.; Correa, R.R.; Rossing, P.; Sjöström, C.D.; Stefánsson, B.V.; Langkilde, A.M.; Wheeler, D.C.; Heerspink, H.J.L. Effects of dapagliflozin in stage 4 chronic kidney disease. J. Am. Soc. Nephrol., 2021, 32(9), 2352-2361.
[http://dx.doi.org/10.1681/ASN.2021020167] [PMID: 34272327]
[80]
Sarafidis, P.A.; Bakris, G.L. The antinatriuretic effect of insulin: An unappreciated mechanism for hypertension associated with insulin resistance? Am. J. Nephrol., 2007, 27(1), 44-54.
[http://dx.doi.org/10.1159/000098955] [PMID: 17245074]
[81]
Artunc, F.; Schleicher, E.; Weigert, C.; Fritsche, A.; Stefan, N.; Häring, H.U. The impact of insulin resistance on the kidney and vasculature. Nat. Rev. Nephrol., 2016, 12(12), 721-737.
[http://dx.doi.org/10.1038/nrneph.2016.145] [PMID: 27748389]
[82]
Cefalu, W.T.; Stenlöf, K.; Leiter, L.A.; Wilding, J.P.H.; Blonde, L.; Polidori, D.; Xie, J.; Sullivan, D.; Usiskin, K.; Canovatchel, W.; Meininger, G. Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. Diabetologia, 2015, 58(6), 1183-1187.
[http://dx.doi.org/10.1007/s00125-015-3547-2] [PMID: 25813214]
[83]
Chino, Y.; Samukawa, Y.; Sakai, S.; Nakai, Y.; Yamaguchi, J.; Nakanishi, T.; Tamai, I. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm. Drug Dispos., 2014, 35(7), 391-404.
[http://dx.doi.org/10.1002/bdd.1909] [PMID: 25044127]
[84]
Heerspink, H.J.L.; Kosiborod, M.; Inzucchi, S.E.; Cherney, D.Z.I. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int., 2018, 94(1), 26-39.
[http://dx.doi.org/10.1016/j.kint.2017.12.027] [PMID: 29735306]
[85]
Heerspink, H.J.L.; Perkins, B.A.; Fitchett, D.H.; Husain, M.; Cherney, D.Z.I. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus. Circulation, 2016, 134(10), 752-772.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.116.021887] [PMID: 27470878]
[86]
Terami, N.; Ogawa, D.; Tachibana, H.; Hatanaka, T.; Wada, J.; Nakatsuka, A.; Eguchi, J.; Horiguchi, C.S.; Nishii, N.; Yamada, H.; Takei, K.; Makino, H. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One, 2014, 9(6), e100777.
[http://dx.doi.org/10.1371/journal.pone.0100777] [PMID: 24960177]
[87]
O’Neill, J.; Fasching, A.; Pihl, L.; Patinha, D.; Franzén, S.; Palm, F. Acute SGLT inhibition normalizes O 2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. Am. J. Physiol. Renal Physiol., 2015, 309(3), F227-F234.
[http://dx.doi.org/10.1152/ajprenal.00689.2014] [PMID: 26041448]
[88]
Chang, Y.K.; Choi, H.; Jeong, J.Y.; Na, K.R.; Lee, K.W.; Lim, B.J.; Choi, D.E. Dapagliflozin, SGLT2 inhibitor, attenuates renal ischemia-reperfusion injury. PLoS One, 2016, 11(7), e0158810.
[http://dx.doi.org/10.1371/journal.pone.0158810] [PMID: 27391020]
[89]
Górriz, J.L.; Navarro, G.J.F.; Ortiz, A.; Vergara, A.; Nuñez, J.; Jacobs-Cachá, C.; Martínez-Castelao, A.; Soler, M.J. Sodium-glucose cotransporter 2 inhibition: Towards an indication to treat diabetic kidney disease. Nephrol. Dial. Transplant., 2020, 35(Suppl. 1), i13-i23.
[http://dx.doi.org/10.1093/ndt/gfz237] [PMID: 32003834]
[90]
Sarafidis, P.A.; Khosla, N.; Bakris, G.L. Antihypertensive therapy in the presence of proteinuria. Am. J. Kidney Dis., 2007, 49(1), 12-26.
[http://dx.doi.org/10.1053/j.ajkd.2006.10.014] [PMID: 17185142]
[91]
Brenner, B.M.; Lawler, E.V.; Mackenzie, H.S. The hyperfiltration theory: A paradigm shift in nephrology. Kidney Int., 1996, 49(6), 1774-1777.
[http://dx.doi.org/10.1038/ki.1996.265] [PMID: 8743495]
[92]
Norton, L.; Shannon, C.E.; Fourcaudot, M.; Hu, C.; Wang, N.; Ren, W.; Song, J.; Abdul-Ghani, M.; DeFronzo, R.A.; Ren, J.; Jia, W. Sodium-glucose co-transporter ( SGLT ) and glucose transporter ( GLUT ) expression in the kidney of type 2 diabetic subjects. Diabetes Obes. Metab., 2017, 19(9), 1322-1326.
[http://dx.doi.org/10.1111/dom.13003] [PMID: 28477418]
[93]
Solini, A.; Rossi, C.; Mazzanti, C.M.; Proietti, A.; Koepsell, H.; Ferrannini, E. Sodium-glucose co-transporter ( SGLT )2 and SGLT1 renal expression in patients with type 2 diabetes. Diabetes Obes. Metab., 2017, 19(9), 1289-1294.
[http://dx.doi.org/10.1111/dom.12970] [PMID: 28419670]
[94]
Cherney, D.Z.I.; Perkins, B.A.; Soleymanlou, N.; Maione, M.; Lai, V.; Lee, A.; Fagan, N.M.; Woerle, H.J.; Johansen, O.E.; Broedl, U.C.; von Eynatten, M. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation, 2014, 129(5), 587-597.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.113.005081] [PMID: 24334175]
[95]
van Bommel, E.J.M.; Muskiet, M.H.A.; van Baar, M.J.B.; Tonneijck, L.; Smits, M.M.; Emanuel, A.L.; Bozovic, A.; Danser, A.H.J.; Geurts, F.; Hoorn, E.J.; Touw, D.J.; Larsen, E.L.; Poulsen, H.E.; Kramer, M.H.H.; Nieuwdorp, M.; Joles, J.A.; van Raalte, D.H. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney Int., 2020, 97(1), 202-212.
[http://dx.doi.org/10.1016/j.kint.2019.09.013] [PMID: 31791665]
[96]
Soler, M.J.; Porrini, E.; Fernandez-Fernandez, B.; Ortiz, A. SGLT2i and postglomerular vasodilation. Kidney Int., 2020, 97(4), 805-806.
[http://dx.doi.org/10.1016/j.kint.2020.01.007] [PMID: 32200864]
[97]
FDA approves treatment for chronic kidney disease. FDA. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-chronic-kidney-disease (Accessed on: 2021-10-27).
[98]
McMurray, J.J.V.; Solomon, S.D.; Inzucchi, S.E.; Køber, L.; Kosiborod, M.N.; Martinez, F.A.; Ponikowski, P.; Sabatine, M.S.; Anand, I.S.; Bělohlávek, J.; Böhm, M.; Chiang, C.E.; Chopra, V.K.; de Boer, R.A.; Desai, A.S.; Diez, M.; Drozdz, J.; Dukát, A.; Ge, J.; Howlett, J.G.; Katova, T.; Kitakaze, M.; Ljungman, C.E.A.; Merkely, B.; Nicolau, J.C.; O’Meara, E.; Petrie, M.C.; Vinh, P.N.; Schou, M.; Tereshchenko, S.; Verma, S.; Held, C.; DeMets, D.L.; Docherty, K.F.; Jhund, P.S.; Bengtsson, O.; Sjöstrand, M.; Langkilde, A.M. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med., 2019, 381(21), 1995-2008.
[http://dx.doi.org/10.1056/NEJMoa1911303] [PMID: 31535829]
[99]
Packer, M.; Anker, S.D.; Butler, J.; Filippatos, G.; Pocock, S.J.; Carson, P.; Januzzi, J.; Verma, S.; Tsutsui, H.; Brueckmann, M.; Jamal, W.; Kimura, K.; Schnee, J.; Zeller, C.; Cotton, D.; Bocchi, E.; Böhm, M.; Choi, D.J.; Chopra, V.; Chuquiure, E.; Giannetti, N.; Janssens, S.; Zhang, J.; Gonzalez Juanatey, J.R.; Kaul, S.; Brunner-La Rocca, H.P.; Merkely, B.; Nicholls, S.J.; Perrone, S.; Pina, I.; Ponikowski, P.; Sattar, N.; Senni, M.; Seronde, M.F.; Spinar, J.; Squire, I.; Taddei, S.; Wanner, C.; Zannad, F. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med., 2020, 383(15), 1413-1424.
[http://dx.doi.org/10.1056/NEJMoa2022190] [PMID: 32865377]
[100]
Fernandez, F.B.; Sarafidis, P.; Kanbay, M.; Navarro, J.F.; Soler, M.J.; Górriz, J.L.; Ortiz, A. SGLT2 inhibitors for non-diabetic kidney disease: Drugs to treat CKD that also improve glycaemia. Clin. Kidney J., 2020, 13(5), 728-733.
[http://dx.doi.org/10.1093/ckj/sfaa198] [PMID: 33123352]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy